Luis Borges Email & Phone Number

Houston, Tx, Us

I wanted to share that, as of yesterday, I have parted ways with Metagenomi by mutual agreement. My time at Metagenomi has been incredibly valuable, and I am grateful for the opportunities and growth I’ve experienced, particularly in learning about gene editing technologies and therapies for genetic disorders.I am now looking forward to new challenges and opportunities, especially in the areas of Oncology, Hematology, and Immunology, where I have spent most of my industry career. If you know of any roles or have any suggestions, please feel free to reach out to me.Thank you to everyone who has supported me on this journey. I am excited about what the future holds and remain committed to developing novel therapies for grievous illnesses.

Emeryville, California, Us

• At Metagenomi, I oversaw the Research organization, leading the development of innovative gene editing tools and product candidates for the treatment of genetic disorders (in vivo gene editing) and autoimmune disorders (ex vivo edited CAR T cells).• I led a team of over 140 researchers working on multiple projects, including:1. Discovery and characterization of novel CRISPR-based systems for gene editing (CRISPR nucleases, Base editors, Prime editors, and large integration CAST and RNA-based systems).2. Development of analytical tools for off-target and specificity analysis.3. Development of gene therapies for conditions such as hemophilia A, TTR, AGT, and other genetic disorders.4. Development of autologous and allogeneic CAR T cell therapies for autoimmunity.• I unified all groups working on various aspects of discovery and drug development (Pre-Clinical, Cell Therapy, Discovery, Specificity and Off-Target analysis) under one organization to enhance coordination and productivity. I implemented a matrix organization to facilitate resource mobility and improve efficiency.• I restructured and refocused the Cell Therapy organization to enable product development from discovery to the clinic and pivoted into autoimmunity to address unmet medical needs in large patient populations.

Philadelphia, Pennsylvania, Us

- Experience leading the development of iPSC-derived cancer cell therapies. At Century, we reprogram somatic cells to generate iPSC lines and differentiate the iPSCs in different immune cell types (current focus in on NK, alpha beta T cells, and gamma delta T cells). We use CRIPR-mediated gene editing to engineer the cells with multiple genetic features that enhance persistence, safety, homing to tumor sites, and tumor cell killing - Experience growing a start-up company and taking it public. When I joined the Century, there were about 15 people and 7-8 people in Research. In about 3.5 years, I lead the buildup of the Research organization to a multi-functional team of more than 100 people spread across three sites (Philadelphia, Seattle, and Hamilton, Canada). Our Research group is split into seven major groups: Gene editing, Protein Sciences, iPSC Biology, Immunology, In vitro and In vivo Pharmacology, Advanced Technologies, and GBM research- Experience fundraising with VC firms and equity investors through multiple rounds of investment. In March 2021, we closed a cross-over round where we raised $160 million. - Experience taking the company public. Immediately after we closed the cross-over round, we started working on the IPO. In less than 4 months and working through virtual meetings with the IPO team, we drafted and filed the S-1 form and went public in June of 2021 raising $242.7 million- Experience with BD opportunities and conducting due diligence activities. In January of 2022, we entered a major collaboration with BMS to develop and commercialize up to four iPSC-derived, engineered NK or T cell programs for hematologic malignancies and solid tumors. Century received $150M in cash ($100M upfront payment and $50M equity investment), with potential for additional $3B in payments plus royalties across multiple programs- Experience managing academic collaborations and SRAs - Experience with IND filings and direct interactions with the FDA

Houston, Texas, Us

Led a multifunctional research organization across multiple geographies: Houston (USA), London (UK), and Zurich (Switzerland).Directed collaboration with King's College in London, UK, to develop therapeutic TCRs for cell therapy targeting solid and liquid tumors.Spearheaded the development of autologous and allogeneic CAR-cell therapies in collaboration with Baylor College of Medicine, based on a novel cell therapy platform using CAR-NKT cells engineered with humanized CARs.Advanced cell therapy product candidates, including an autologous GD2-CAR NKT cell therapy for neuroblastoma, and two allogeneic NKT cell products: one targeting CD19 for B cell malignancies and another targeting GPC3 for hepatocellular carcinoma.- Experience leading and managing collaborations with academic institutions in the USA and overseas (UK)- Experience with BD opportunities and external diligence- Experience building a Research organization across multiple geographies: Houston (USA), London (UK), and Zurich (Switzerland)- Experience with IND filings - Experience fundraising with equity investors

• Transitioned the company from a platform-based enterprise to a drug development company focused on cancer immunotherapy. Restructured and expanded the R&D team to cover all aspects of drug development.• Built new groups, including the Immunology and Antibody Discovery & Protein Engineering teams, to develop multiple biologic agents aimed at blocking immune checkpoints, activating effector T cells, and inhibiting regulatory T cells. These agents included Fc-fusion proteins, multivalent activating VHH antibodies, checkpoint blockers, bi-specific T cell engagers, and ADCC-enhanced antibodies. • Discovered and advanced three drug candidates to IND-enabling studies, including a CD80-FC fusion protein (FPT155), a B7-H4 blocking antibody (FPT150), and a tetravalent anti-GITR antibody (FPA154). Two of these candidates, FPT155 and FPT150, successfully reached clinical trials.

Thousand Oaks, Ca, Us

Late in 2011, I transition from Oncology to the newly Therapeutic Innovation Unit to explore novel biology and approaches for cancer immunotherapy. My group was responsible for developing new approaches and agents for re-directed T cell killing and for investigating novel approaches to engage different immune cell subsets to control tumor growth.

Thousand Oaks, Ca, Us

• Developed next-generation BiTE antibodies for cancer treatment, utilizing Fc-based scaffolds to extend their half-life and efficacy. These new agents employed various scaffolds to combine the two binding domains, grafted onto an engineered Fc-region designed to enable the dimerization of two different chains, prevent ADCC, and manipulate pharmacokinetics.• The half-life extended (HLE) bi-specific engagers that Amgen is currently developing are based on one of the scaffolds created by my group.• Created bi-specific engagers that recruit not only T cells but also other immune cells, including NK cells and macrophages.

Thousand Oaks, Ca, Us

• Developed novel agonistic antibodies targeting EpoR and led multiple biologics programs, including antibody-drug conjugates for ovarian cancer and ADCC-engineered antibodies for various malignancies.• Supported late-stage clinical candidates and approved biologics including Kepivance, Epogen, Aranesp, Neupogen, and Neulasta.• Supported the BLA filing for Kepivance in the US and Europe.

Thousand Oaks, Ca, Us

Department of Oncology and Hematology

Thousand Oaks, Ca, Us

Us

• Developed cancer immunotherapies focused on enhancing dendritic and T-cell functions by using cytokines such as FLT3L and CD40L to stimulate the adaptive immune system.• Identified and characterized Leukocyte Immunoglobulin-like Receptors (LIRs, later renamed LILRs).

Us

Seattle, Wa, Us

Department of Pathology, School of Medicine

Ph.D, Department Of Pathology

Marine Biology